Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Curis Inc..
Curis Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Curis Inc. are also analyzed.
Detailed SWOT Analysis of the company including key strengths and weaknesses of Curis Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed.
Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided.
Financial analysis of Curis Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Curis Inc. and all latest updates of the company are provided.
The 2025 version of Curis Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.
TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 Introduction to the Company
2.1 Curis Inc.- Key Facts
2.2 Curis Inc.- Geographic Locations
2.3 Curis Inc.- Subsidiaries and Affiliates
2.4 Curis Inc.- Business Divisions
2.5 Curis Inc.- Key Employees
2.5.1 Management Team
2.5.2 Board of Directors
3. Curis Inc. Strategic Analysis Review
3.1 Curis Inc.- Key Strategies
3.2 Curis Inc.- Company Outlook Statement
3.3 Curis Inc.- SWOT Analysis
3.3.1 Curis Inc.- Key Strengths
3.3.2 Curis Inc.- Key Weaknesses
3.3.3 Curis Inc.- Potential Opportunities
3.3.4 Curis Inc.- Potential Threats
3.4 Curis Inc.- Key Competitors
4. Business Description of the Company
4.1 Curis Inc.- Business Overview
4.2 Curis Inc.- Operations by Segment
5 Products and Services Details
5.1 Curis Inc.- Key Products
5.2 Curis Inc.- Key Service Areas
5.3 Curis Inc.- Key Brands
6 Company Developments
6.1 Curis Inc.- Company History
6.2 Curis Inc.- Latest Developments
7 Financial Analysis
7.1 Curis Inc.- Income Statements
7.2 Curis Inc.- Balance Sheet
7.3 Curis Inc.- Cash Flow Statements
8 Competitors and Industry Analysis
8.1 Curis Inc.- Direct Competitors
8.2 Curis Inc.- Competitor Financial Ratios comparison
8.3 Curis Inc.- Competitor Stock Charts Comparison
8.4 Curis Inc.- Industry Analysis
9 Appendix
9.1 About SWOTreports
9.2 Sources and Methodology
9.3 Contact Information
P.S.Financial Analysis will be provided only for companies reporting financial data.
At SWOT Reports, we understand the importance of informed decision-making in today's dynamic business landscape. To help you experience the depth and quality of our market research reports, we offer complimentary samples tailored to your specific needs.
Start Now! Please fill the form below for your free sample.
Evaluate Our Expertise: Our reports are crafted by industry experts and seasoned analysts. Requesting a sample allows you to assess the depth of research and the caliber of insights we provide.
Tailored to Your Needs: Let us know your industry, market segment, or specific topic of interest. Our free samples are customized to ensure relevance to your business objectives.
Witness Actionable Insights: See firsthand how our reports go beyond data, offering actionable insights and strategic recommendations that can drive your business forward.
Embark on your journey towards strategic decision-making by requesting a free sample from SWOT Reports. Experience the caliber of insights that can transform the way you approach your business challenges.
Gain valuable insights into the company for academic or business research purposes with this comprehensive profile. Key elements, such as SWOT analysis and corporate strategy, are included to support your research needs effectively.
Customer and Supplier Identification: Analyze the company’s business structure, operations, major products, services, and strategies to identify potential customers and suppliers.
Leverage a detailed SWOT analysis to understand and evaluate your competitors' business structures, strategies, and core performance metrics. This analysis offers an up-to-date and objective perspective on the company’s strengths, weaknesses, opportunities, and threats.
Didn’t find what you’re looking for? TALK TO OUR ANALYST TEAM
Need something within your budget? NO WORRIES! WE GOT YOU COVERED!